Results 141 to 150 of about 674,775 (259)

Leveraging remnant viral load samples for SARS-CoV-2 antibody seroprevalence trends among PLHIV in Kenya, February 2021-October 2022: a cross-sectional surveillance survey. [PDF]

BMJ Public Health
Chun H, Waruru A, Wafula R, Makokha E, Cheti E, Opollo VS, Joseph R, Dirlikov E, Bulterys M, Patel H, Junghae M, Kiiru J, Kariuki D, Achieng R, Wezuma M, Maina A, Kirui E, Odhiambo N, Carter JY, Schmitz M, Aman R, Bowen N, Kingwara L, Umuro M, Wanyama D, Ouma Ndiege K, Aoko A, Shiraishi R.   +27 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Development of a Robotic Training Curriculum for Visceral and Gastrointestinal Surgical Trainees: An International Delphi Study. [PDF]

United European Gastroenterol J
Fadel MG, Walshaw J, Yiasemidou M, Boal M, Pecchini F, Elhadi M, Massey LH, Carrano FM, Fehervari M, Walsh CM, Boshier PR, Eckhoff J, Buckle P, ERSC Study Group, Gisbertz SS, Bouvy N, Arezzo A, Perretta S, Nickel F, Khan J, Hanna GB, Seeliger B, Antoniou SA, Fuchs HF, Francis NK, Kontovounisios C.   +25 more
europepmc   +2 more sources

Performance of Large Language Models in Answering Healthcare Delivery Questions: A Quantitative Cross-Sectional Study. [PDF]

Health Sci Rep
Khosravi M, Zamaninasab Z, Khosravi F, Attar M, Arab-Zozani M.   +4 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

A high-throughput, streamlined cloning protocol to generate guide RNAs for CRISPR activation. [PDF]

Front Genome Ed
Zhu S, Tamez González AA, Alokda A, Van Raamsdonk JM.   +3 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

'Guard' Workout: Can a Lifeguard-Specific High-Intensity Functional Training Reflect Rescue Demands? [PDF]

J Funct Morphol Kinesiol
Ignacio-Rodríguez I, Aranda-García S, Sanmartín-Montes M, Morales-Rejas O, Otero-Agra M, Santos-Folgar M, Zarzosa-Alonso F, Barcala-Furelos R.   +7 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source